Pyxis Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PYXS research report →
About the company
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.
- CEO
- Thomas Civik
- IPO
- 2021
- Employees
- 44
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $166.62M
- P/E
- -2.01
- P/S
- 12.02
- P/B
- 5.34
- EV/EBITDA
- -2.34
- Div Yield
- 0.00%
- Gross Margin
- 99.81%
- Op Margin
- -619.61%
- Net Margin
- -589.80%
- ROE
- -135.60%
- ROIC
- -173.38%
- Revenue
- $13.86M · -14.17%
- Net Income
- $-79,621,000 · -2.96%
- EPS
- $-1.28 · 3.03%
- Op Income
- $-84,420,000
- FCF YoY
- -9.67%
- 52W High
- $5.55
- 52W Low
- $0.97
- 50D MA
- $2.03
- 200D MA
- $2.33
- Beta
- 1.31
- Avg Volume
- 769.55K
Get TickerSpark's AI analysis on PYXS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Dupont Jakob | other | 35,000 |
| Jun 30, 26 | Dupont Jakob | other | 35,000 |
| Jun 30, 26 | Dupont Jakob | sell | 35,000 |
| Mar 24, 26 | Dupont Jakob | other | 45,867 |
| Mar 24, 26 | Wadhane Jitendra | other | 109,461 |
| Mar 24, 26 | Wadhane Jitendra | other | 262,635 |
| Mar 24, 26 | FLAVIN JOHN L | other | 45,867 |
| Mar 24, 26 | Metzger Michael A | other | 45,867 |
| Mar 24, 26 | Lewis-Hall Freda C | other | 45,867 |
| Mar 24, 26 | Cline Darren S | other | 45,867 |
Our PYXS coverage
Recent articles, reports, and earnings notes.
No research on PYXS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PYXS report →Similar companies
Peers in the same neighborhood.